Pulse Biosciences (NASDAQ:PLSE) Trading Down 5.5% – Time to Sell?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price traded down 5.5% during mid-day trading on Wednesday . The stock traded as low as $16.02 and last traded at $16.10. 126,873 shares were traded during mid-day trading, a decline of 37% from the average session volume of 202,334 shares. The stock had previously closed at $17.04.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Tuesday, November 12th.

Pulse Biosciences Trading Down 5.3 %

The firm has a fifty day moving average price of $17.31 and a 200 day moving average price of $15.24.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the prior year, the business earned ($0.19) earnings per share.

Institutional Trading of Pulse Biosciences

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after buying an additional 189,227 shares during the period. State Street Corp grew its stake in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares during the period. Geode Capital Management LLC lifted its holdings in Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after acquiring an additional 97,565 shares in the last quarter. Finally, Westside Investment Management Inc. lifted its holdings in shares of Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after purchasing an additional 31,440 shares in the last quarter. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.